Neuromodulation device company SetPoint Medical has raised $140 million to commercialize its SetPoint System, designed to treat rheumatoid arthritis. The company’s new device is used to treat adults with moderate to severe rheumatoid arthritis who haven’t responded to or cannot tolerate other therapies. Abbott, Boston Scientific and Northwell Health are among the investors.

SetPoint Medical nabs $140M to commercialize neuromod device

SetPoint Medical has raised $140 million in funding to commercialize its SetPoint System, a neuromodulation device designed to treat adults with moderate to severe rheumatoid arthritis who have not responded to or cannot tolerate other therapies. Investors include Abbott, Boston Scientific, and Northwell Health.